HSCT outcome in relation to DC analyses
| Patient population . | DC measurement . | Outcome . | Reference . |
|---|---|---|---|
| Allo-HSCT (n = 49) | Total PB DC count at engraftment < 4.97 cells/μL | Survival ↓ | 64 |
| 92% PBSCT; 73% MAC | Relapse and aGVHD ↑ | ||
| Low PB mDCs (CD11c+) at engraftment | Survival ↓ | ||
| Relapse and aGVHD ↑ | |||
| Low PB pDCs (CD123+) at engraftment | aGVHD ↑ | ||
| Graft DC or DC count before transplant | No association with death/relapse | ||
| Allo-HSCT (n = 30) | Higher PB pDCs (BDCA-2+) > day 100 (donor) | cGVHD ↑ | 83 |
| 63% PBSCT; 83% MAC | |||
| Allo-HSCT (n = 24) | Higher total PB host DCs day 100 | Survival ↓ | 84 |
| 100% BM; 87% RIC | aGVHD and cGVHD (grade II-IV)↑ | ||
| Allo-HSCT (n = 40) | Low total PB DC, mDC (CD11c+), and pDC (CD123hi) counts | GVHD severity ↑ | 85 |
| 90% PBSCT; 52% RIC | > 7.9% CMRF-44+ CD11c+ DCs | aGVHD ↑ (sensitivity, 87.5%; specificity, 79.2%) | |
| CD83+/CD86+ CD11c+ DCs | No association with aGVHD | ||
| Allo-HSCT (n = 69) | Graft pDC (CD123+) > 2.3 × 106/kg | Relapse ↑ | 63 |
| 100% PBSCT; 54% MAC | OS and EFS ↓ | ||
| Allo-HSCT (n = 54) | Lower PB pDCs (lin−/CD11c−/ILT3+) 3 mo after HSCT (median 92 days) | aGVHD (grade II-IV) ↑ | 88 |
| 93% PBSCT; 100% RIC | OS and NRM ↓ | ||
| Late infections ↑ | |||
| Death ↑ | |||
| Patient population . | DC measurement . | Outcome . | Reference . |
|---|---|---|---|
| Allo-HSCT (n = 49) | Total PB DC count at engraftment < 4.97 cells/μL | Survival ↓ | 64 |
| 92% PBSCT; 73% MAC | Relapse and aGVHD ↑ | ||
| Low PB mDCs (CD11c+) at engraftment | Survival ↓ | ||
| Relapse and aGVHD ↑ | |||
| Low PB pDCs (CD123+) at engraftment | aGVHD ↑ | ||
| Graft DC or DC count before transplant | No association with death/relapse | ||
| Allo-HSCT (n = 30) | Higher PB pDCs (BDCA-2+) > day 100 (donor) | cGVHD ↑ | 83 |
| 63% PBSCT; 83% MAC | |||
| Allo-HSCT (n = 24) | Higher total PB host DCs day 100 | Survival ↓ | 84 |
| 100% BM; 87% RIC | aGVHD and cGVHD (grade II-IV)↑ | ||
| Allo-HSCT (n = 40) | Low total PB DC, mDC (CD11c+), and pDC (CD123hi) counts | GVHD severity ↑ | 85 |
| 90% PBSCT; 52% RIC | > 7.9% CMRF-44+ CD11c+ DCs | aGVHD ↑ (sensitivity, 87.5%; specificity, 79.2%) | |
| CD83+/CD86+ CD11c+ DCs | No association with aGVHD | ||
| Allo-HSCT (n = 69) | Graft pDC (CD123+) > 2.3 × 106/kg | Relapse ↑ | 63 |
| 100% PBSCT; 54% MAC | OS and EFS ↓ | ||
| Allo-HSCT (n = 54) | Lower PB pDCs (lin−/CD11c−/ILT3+) 3 mo after HSCT (median 92 days) | aGVHD (grade II-IV) ↑ | 88 |
| 93% PBSCT; 100% RIC | OS and NRM ↓ | ||
| Late infections ↑ | |||
| Death ↑ | |||
PBSCT indicates peripheral blood stem cell transplant; EFS, event-free survival; ILT3, immunoglobulin-like transcript 3; and NRM, nonrelapse mortality.